Cooper Companies (NASDAQ:COO) PT Raised to $125.00

Cooper Companies (NASDAQ:COO) had its price target hoisted by Robert W. Baird from $118.00 to $125.00 in a research note published on Thursday, Benzinga reports. They currently have an outperform rating on the medical device company’s stock.

COO has been the subject of several other reports. Wells Fargo & Company upped their target price on Cooper Companies from $110.00 to $115.00 and gave the stock an overweight rating in a report on Thursday. Piper Sandler upped their target price on Cooper Companies from $115.00 to $120.00 and gave the stock an overweight rating in a report on Thursday. Jefferies Financial Group upgraded Cooper Companies from a hold rating to a buy rating and upped their target price for the stock from $107.00 to $115.00 in a report on Tuesday, July 16th. Finally, Needham & Company LLC reiterated a hold rating on shares of Cooper Companies in a report on Friday, August 23rd. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $113.61.

Cooper Companies Price Performance

COO opened at $105.73 on Thursday. The business has a fifty day moving average of $91.53 and a 200 day moving average of $94.22. Cooper Companies has a 52-week low of $75.93 and a 52-week high of $106.95. The company has a quick ratio of 1.14, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The stock has a market cap of $21.05 billion, a P/E ratio of 62.10, a PEG ratio of 2.56 and a beta of 0.98.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.05. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $997.30 million. During the same quarter in the previous year, the business earned $0.84 EPS. Cooper Companies’s revenue was up 7.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Cooper Companies will post 3.66 EPS for the current year.

Institutional Investors Weigh In On Cooper Companies

A number of hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers increased its position in Cooper Companies by 6.3% during the 2nd quarter. Cetera Investment Advisers now owns 22,244 shares of the medical device company’s stock valued at $1,942,000 after buying an additional 1,309 shares in the last quarter. B. Riley Wealth Advisors Inc. increased its position in Cooper Companies by 113.1% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 2,529 shares of the medical device company’s stock valued at $221,000 after buying an additional 1,342 shares in the last quarter. Quarry LP increased its position in Cooper Companies by 1,225.9% during the 2nd quarter. Quarry LP now owns 2,718 shares of the medical device company’s stock valued at $237,000 after buying an additional 2,513 shares in the last quarter. Wallace Advisory Group LLC acquired a new position in Cooper Companies during the 2nd quarter valued at about $290,000. Finally, Northwestern Mutual Wealth Management Co. increased its position in Cooper Companies by 23.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,868 shares of the medical device company’s stock valued at $163,000 after buying an additional 354 shares in the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.